EyePoint Pharmaceuticals, Inc. (EYPT) — Financial statements
Income statement, balance sheet, and cash flow for EyePoint Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 31↓27.5% | 43↓6.0% | 46↑11.1% | 41↑12.1% | 37 | |
| Cost of Revenue | 2↓44.3% | 4↓19.9% | 5↓44.4% | 8↑1.8% | 8 | |
| Gross Profit | 29↓25.9% | 40↓4.4% | 41↑25.1% | 33↑15.0% | 29 | |
| Operating Expenses | ||||||
| R&D Expenses | 221↑66.3% | 133↑105.6% | 65↑30.3% | 50↑74.2% | 29 | |
| General & Administrative Expenses | 52↓1.4% | 52↑30.6% | 40↑15.2% | 35↑36.1% | 26 | |
| Selling & Marketing Expenses | 0.09↓31.3% | 0.13↓98.9% | 12↓54.2% | 26↓7.3% | 28 | |
| SG&A Expenses | 52↓1.5% | 52↑1.3% | 52↓14.1% | 60↑13.7% | 53 | |
| Other Expenses | 0.00 | 0.00 | 0.00↓100.0% | 23↑824.8% | 2 | |
| Operating Expenses | 273↑47.1% | 185↑59.2% | 116↓12.3% | 133↑57.9% | 84 | |
| Total Costs & Expenses | 275↑45.3% | 189↑56.2% | 121↓14.1% | 141↑52.9% | 92 | |
| Operating Results | ||||||
| Operating Income | -243↓66.9% | -146↓94.3% | -75↑24.7% | -100↓80.3% | -55 | |
| Depreciation & Amortization | 0.00↓100.0% | 2↑231.9% | 0.46↓81.0% | 2↓11.7% | 3 | |
| EBITDA | -243↓88.4% | -129↓87.3% | -69↑28.6% | -97↓92.7% | -50 | |
| EBIT | -243↓86.2% | -131↓88.2% | -69↑29.9% | -99↓87.2% | -53 | |
| Interest & Other Income | ||||||
| Net Interest Income | 12↓22.0% | 15↑164.4% | 6↑638.9% | -1↑79.7% | -5 | |
| Interest Income | 12↓22.1% | 15↑117.1% | 7↑226.1% | 2↑629.8% | 0.29 | |
| Interest Expense | -0.03↓335.7% | 0.01↓98.9% | 1↓60.9% | 3↓42.0% | 5 | |
| Non-Operating Income | 0.00↑100.0% | -15↓169.3% | -6↓879.4% | -0.57↑75.7% | -2 | |
| Other Income / Expenses | 12↓22.0% | 15↑246.1% | 4↑266.4% | -3↑16.7% | -3 | |
| Income Before Tax | -232↓77.2% | -131↓84.9% | -71↑30.8% | -102↓75.0% | -58 | |
| Income Tax Expense | 0.28↑210.0% | 0.09↑8.4% | 0.08 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -232↓77.2% | -131↓84.9% | -71↑30.8% | -102↓75.0% | -58 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -232↓77.2% | -131↓84.9% | -71↑30.8% | -102↓75.0% | -58 | |
| Bottom-Line Net Income | -232↓77.2% | -131↓84.9% | -71↑30.8% | -102↓75.0% | -58 | |
| EPS (Basic) | -3.17↓36.6% | -2.32↓27.5% | -1.82↑33.6% | -2.74↓35.0% | -2.03 | |
| EPS (Diluted) | -3.17↓36.6% | -2.32↓27.5% | -1.82↑33.6% | -2.74↓35.0% | -2.03 | |
| Weighted Average Shares | 73↑30.1% | 56↑44.7% | 39↑4.3% | 37↑29.8% | 29 | |
| Weighted Average Diluted Shares | 73↑30.1% | 56↑44.7% | 39↑4.3% | 37↑29.8% | 29 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.